Publication: Drug Discovery and Development

First reported 8 hours ago - Updated 4 hours ago - 1 reports

Takeda, Orexigen Announce Availability of Weight-Management Drug

Takeda Pharmaceutical Company Ltd. ("Takeda"), its wholly-owned subsidiary Takeda Pharmaceuticals U.S.A., Inc. and Orexigen Therapeutics, Inc. jointly announced that Contrave (naltrexone HCI and bupropion HCI) extended-release tablets are now available ... [Published Drug Discovery and Development - 8 hours ago]
First reported 8 hours ago - Updated 5 hours ago - 1 reports

Sanofi, Regeneron Announce Phase 3 Study of Atopic Dermatitis Drug

Sanofi and Regeneron Pharmaceuticals, Inc.  announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe  atopic dermatitis ... [Published Drug Discovery and Development - 8 hours ago]
First reported 6 hours ago - Updated 5 hours ago - 1 reports

Taiho Receives FDA Fast Track Designation for Colorectal Cancer Drug

Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an oral ... [Published Drug Discovery and Development - 6 hours ago]
First reported 6 hours ago - Updated 6 hours ago - 1 reports

Clanotech Receives Orphan Drug Designation in the EU

Clanotech AB announced that its anti-fibrotic and anti-angiogenic candidate drug CLT-28643 received orphan drug designation by the European Medicines Agency (EMA) for prevention of scarring post glaucoma filtration surgery. Karolinska Development has ... [Published Drug Discovery and Development - 6 hours ago]
First reported 6 hours ago - Updated 6 hours ago - 1 reports

Revalesio’s Drug Has Potential to Treat Alzheimer’s Disease

Revalesio Corporation and Rush University Medical Center’s Department of Neurological Sciences published findings from two research studies that demonstrate the potential for RNS60 to treat Alzheimer’s disease and other forms of dementia by protecting neuronal ... [Published Drug Discovery and Development - 6 hours ago]
First reported Oct 17 2014 - Updated Oct 17 2014 - 1 reports

Pharmacyclics' Non-Chemo Treatment Approved in Europe

Pharmacyclics Inc. announced that the European Commission (EC) has granted marketing approval for Imbruvica (ibrutinib) throughout the 28 member states of the European Union (EU). Imbruvica, a first-in-class, oral, once-daily, non-chemotherapy treatment, ... [Published Drug Discovery and Development - Oct 17 2014]
First reported Oct 17 2014 - Updated Oct 17 2014 - 1 reports

A Novel Approach to Alzheimer’s Disease

Alzheimer's disease (AD) afflicts more than 5 million people in the U.S. and 40 million worldwide, generating annual healthcare costs that exceed $200 billion in the U.S. and $600 billion globally. By 2050, AD is expected to strike more than 115 million ... [Published Drug Discovery and Development - Oct 17 2014]
First reported Oct 17 2014 - Updated Oct 17 2014 - 1 reports

UCSF, CDRD Sign Drug Development Agreement

UC San Francisco and The Centre for Drug Research and Development (CDRD), a non-profit drug development center headquartered in Vancouver, Canada, announced a collaborative affiliation to identify potential medications and develop them to the stage where ... [Published Drug Discovery and Development - Oct 17 2014]
First reported Oct 17 2014 - Updated Oct 17 2014 - 1 reports

Anoro's COPD Drug Shows Improved Lung Function

Respiratory Medicine has published positive results from a third lung function study comparing the efficacy and safety of Anoro Ellipta (umeclidinium /vilanterol, ‘UMEC/VI’), the combination long-acting muscarinic antagonist (LAMA) / long-acting beta2-adrenergic ... [Published Drug Discovery and Development - Oct 17 2014]
First reported Oct 16 2014 - Updated Oct 16 2014 - 1 reports

FDA Fast Tracks Approval of Two ‘Historic’ IPF Drugs

Two historic drugs for idiopathic pulmonary fibrosis (IPF) received “fast track, priority review, orphan product, and breakthrough designation” approval Wednesday from the Food and Drug Administration (FDA).The move drew cheers from top IPF experts, most ... [Published Drug Discovery and Development - Oct 16 2014]
First reported Oct 16 2014 - Updated Oct 16 2014 - 1 reports

Eli Lilly's Lechleiter Honored as Watanabe Life Sciences Champion of the Year

BioCrossroads awarded John C. Lechleiter, Ph.D., chairman, president and CEO of Eli Lilly and Company, with the August M. Watanabe Life Sciences Champion of the Year Award, a prestigious honor named in tribute to BioCrossroads' late first Chairman.BioCrossroads ... [Published Drug Discovery and Development - Oct 16 2014]
First reported Oct 16 2014 - Updated Oct 16 2014 - 1 reports

FDA Approves Boehringer Ingelheim's Drug for Lung Disease

Boehringer Ingelheim Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) approved OFEV (nintedanib) capsules for oral use for the treatment of idiopathic pulmonary fibrosis (IPF). Granted Breakthrough Therapy designation during ... [Published Drug Discovery and Development - Oct 16 2014]

Quotes

...that TAS-102 has been granted Fast Track designation," said Fabio Benedetti, senior vice president and chief medical officer at Taiho Oncology. "Patients with metastatic colorectal cancer, whose disease has progressed after treatment with standard therapies, have limited treatment options to manage their disease. We have initiated our rolling NDA submission to the FDA, and are committed to submitting the rest of the filing as efficiently as possible."
...and that we are able to provide eligible patients with additional offerings," said Douglas Cole, president, Takeda Pharmaceuticals U S A Inc. "These offerings include the Scale Down program, a support program for weight management, and Contrave Direct Save, which helps eligible patients to get Contrave at the lowest cost available to them, which can help to support a patient's complete approach to weight management."
...will have a first-in-class, oral, single-agent, non-chemotherapy treatment option in Imbruvica," said Bob Duggan, Chairman & CEO of Pharmacyclics. "This approval underscores the compelling safety and efficacy benefits of Imbruvica, including statistically significant improvement in overall survival and progression-free survival in CLL and the overall robustness of the data in MCL."
...people even beginning to talk about this region's need for something like BioCrossroads," said David L Johnson, president and CEO, BioCrossroads. "He was one of our original organizers and supporters in 2002, and ever since, he has worked strategically and ceaselessly to engage both his colleagues at Lilly and leaders across the broader community to push ourselves forward to become the best we can possibly be when it comes to developing truly world-class life sciences assets, investments and talent here, culminating in his championship of our efforts to drive the creation of the new Indiana Biosciences Research Institute."

More Content

All (75) | News (75) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Clanotech Receives Orphan Drug Designation in t... [Published Drug Discovery and Development - 6 hours ago]
Taiho Receives FDA Fast Track Designation for C... [Published Drug Discovery and Development - 6 hours ago]
Revalesio’s Drug Has Potential to Treat Alzheim... [Published Drug Discovery and Development - 6 hours ago]
Takeda, Orexigen Announce Availability of Weigh... [Published Drug Discovery and Development - 8 hours ago]
Sanofi, Regeneron Announce Phase 3 Study of Ato... [Published Drug Discovery and Development - 8 hours ago]
A Novel Approach to Alzheimer’s Disease [Published Drug Discovery and Development - Oct 17 2014]
UCSF, CDRD Sign Drug Development Agreement [Published Drug Discovery and Development - Oct 17 2014]
Pharmacyclics' Non-Chemo Treatment Approved in ... [Published Drug Discovery and Development - Oct 17 2014]
Anoro's COPD Drug Shows Improved Lung Function [Published Drug Discovery and Development - Oct 17 2014]
Eli Lilly's Lechleiter Honored as Watanabe Lif... [Published Drug Discovery and Development - Oct 16 2014]
FDA Fast Tracks Approval of Two ‘Historic’ IPF ... [Published Drug Discovery and Development - Oct 16 2014]
FDA Approves Boehringer Ingelheim's Drug for Lu... [Published Drug Discovery and Development - Oct 16 2014]
Noven Announces Menopause Drug's Effects on Wei... [Published Drug Discovery and Development - Oct 15 2014]
Study Finds Neurons "Fine Tune" At Genetic Level [Published Drug Discovery and Development - Oct 15 2014]
Selecta, JDRF, Sanofi Collaborate on SVP Immuno... [Published Drug Discovery and Development - Oct 15 2014]
BMS, Pharmacyclics and Janssen Collaborate on N... [Published Drug Discovery and Development - Oct 13 2014]
Nuvilex Applies for Orphan Drug Designation for... [Published Drug Discovery and Development - Oct 13 2014]
Next Generation Phenotypic Screening: Part of a... [Published Drug Discovery and Development - Oct 11 2014]
Janssen Seeks Approval of Psoriasis Drug [Published Drug Discovery and Development - Oct 10 2014]
Shaping the Future of Immunotherapy: Four Trend... [Published Drug Discovery and Development - Oct 10 2014]
NIH Invests Nearly $32M to Increase Utility of ... [Published Drug Discovery and Development - Oct 09 2014]
Purdue Pharma Launches Smaller Dosage of Chroni... [Published Drug Discovery and Development - Oct 09 2014]
AstraZeneca Gets Positive Results for Asthma Drug [Published Drug Discovery and Development - Oct 09 2014]
NIH to Study More Than 200 Rare Diseases [Published Drug Discovery and Development - Oct 08 2014]
Drug Cured 16 of 16 Monkeys with Viral Ebola Re... [Published Drug Discovery and Development - Oct 08 2014]
Vivolux Cancer Drug Receives FDA Clearance for ... [Published Drug Discovery and Development - Oct 07 2014]
Manzo Pharmaceuticals' Probiotic Will Not Need ... [Published Drug Discovery and Development - Oct 07 2014]
Stratophase Announces Results From Collaboratio... [Published Drug Discovery and Development - Oct 07 2014]
Advances in Protein Detection and Quantitation ... [Published Drug Discovery and Development - Oct 07 2014]
BMS to Study Opdivo in Combination with Novarti... [Published Drug Discovery and Development - Oct 06 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.